Update of SEPAR Guideline “Diagnosis and Treatment of Drug-Resistant Tuberculosis”

Caminero, 2017, Diagnosis and Treatment of Drug-Resistant Tuberculosis, Arch Bronconeumol, 53, 501, 10.1016/j.arbres.2017.02.006 Fregonese, 2018, Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis, Lancet Respir Med, 6, 265, 10.1016/S2213-2600(18)30078-X Ahmad, 2018, The Collaborative Group for the Meta-analysis of Individual Patient Data in MDR-TB Treatment 2017 Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual data and meta-analysis, Lancet, 392, 821, 10.1016/S0140-6736(18)31644-1 Schnippel, 2018, Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study, Lancet Respir Med, 6, 699, 10.1016/S2213-2600(18)30235-2 World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization Document 2018. Licence: CC BY-NC-SA 3.0 IGO. WHO/CDS/TB/2018.7: 1-31. Available from: https://www.who.int/tb/publications/2018/WHO_guidelines_isoniazid_resistant_TB/en/ [accessed 21.01.20]. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/ [accessed 21.01.20]. Nahid, 2019, Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline, Am J Respir Crit Care Med, 200, e93, 10.1164/rccm.201909-1874ST World Health Organization, 2020 2019 2020 Global Laboratory Initiative, 2017 Dorman, 2018, Xpert MTB/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study, Lancet Infect Dis, 18, 76, 10.1016/S1473-3099(17)30691-6 Shah, 2019, Multicenter study of the accuracy of the BD MAX™ MDR-TB assay for detection of Mycobacterium tuberculosis complex and mutations associated with resistance to rifampin and isoniazid, Clin Infect Dis, 10.1093/cid/ciz932 Lee, 2019, Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: cost-effectiveness analysis for India's public sector, PLOS ONE, 14, e0218890, 10.1371/journal.pone.0218890 Miotto, 2017, A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis, Eur Respir J, 50, 1701354, 10.1183/13993003.01354-2017 2018, Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing, N Engl J Med, 379, 1403, 10.1056/NEJMoa1800474 Moreno-Molina, 2019, The future of TB resistance diagnosis: the essentials on whole genome sequencing and rapid testing methods, Arch Bronconeumol, 55, 421, 10.1016/j.arbres.2019.01.002 Fox, 1999, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, S231 Caminero, 2019, Multidrug-resistant tuberculosis, Lancet, 394, 298, 10.1016/S0140-6736(19)30696-8 Caminero, 2019, The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines, Eur Respir J, 54, 1901272, 10.1183/13993003.01272-2019 Caminero, 2015, Classification of anti-TB drugs: a new potential proposal based on the most recent evidence, Eur Respir J, 46, 887, 10.1183/13993003.00432-2015 Caminero, 2018, Treatment of drug-susceptible and drug-resistant tuberculosis, 152 Bloemberg, 2015, Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis, N Eng J Med, 373, 1986, 10.1056/NEJMc1505196 De Vos, 2019, Bedaquiline microheteroresistance after cessation of tuberculosis treatment, N Engl J Med, 380, 2178, 10.1056/NEJMc1815121 Gegia, 2017, Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis, Lancet Infect Dis, 17, 223, 10.1016/S1473-3099(16)30407-8 Ahmad Khan, 2017, Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analysis, Eur Respir J, 50, 1700061, 10.1183/13993003.00061-2017 Nunn, 2019, A trial of a shorter regimen for rifampin-resistant tuberculosis, N Eng J Med, 10.1056/NEJMoa1811867 Taubel, 2010, Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers, Br J Clin Pharmacol, 69, 391, 10.1111/j.1365-2125.2009.03595.x Pontali, 2019, Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives, Eur Respir Rev, 28, 190035, 10.1183/16000617.0035-2019 Alliance, 2019 TB Alliance. FDA approves new treatment for highly drug-resistant forms of tuberculosis. Available from: https://www.tballiance.org/news/fda-approves-new-treatment-highly-drug-resistant-forms-tuberculosis [accessed 24.01.20]. Conradie, 2020, Treatment of highly drug-resistant pulmonary tuberculosis, N Engl J Med, 382, 893, 10.1056/NEJMoa1901814 Ignatius, 2019, New drugs for the treatment of tuberculosis, Clin Chest Med, 40, 811, 10.1016/j.ccm.2019.08.001 Menzies, 2019, Multidrug-resistant tuberculosis. Authors’ reply, Lancet, 394, 299, 10.1016/S0140-6736(19)30692-0 2018 Abdool Karim, 2010, Timing of initiation of antiretroviral drugs during tuberculosis therapy, N Engl J Med, 362, 697, 10.1056/NEJMoa0905848 Blanc, 2011, Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis, N Engl J Med, 365, 1471, 10.1056/NEJMoa1013911 2016 Panel de Expertos del Grupo de estudio de Sida (Gesida-SEIMC). Recomendaciones de Gesida sobre el tratamiento de la tuberculosis en adultos infectados por el virus de la inmunodeficiencia humana (actualización mayo de 2018). Available from: http://gesida-seimc.org/wp-content/uploads/2018/06/gesida_TB_en_VIH_Version_FINAL_5_de_junio_2018.pdf [accessed 13.01.20]. Letang, 2019, Tuberculosis-HIV co-infection: progress and challenges after two decades of global antiretroviral treatment roll-out, Arch Bronconeumol 2019 Harausz, 2015, QTc prolongation and treatment of multidrug-resistant tuberculosis, Int J Tuberc Lung Dis, 19, 385, 10.5588/ijtld.14.0335 Yoon, 2017, Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease, Int J Tuberc Lung Dis, 21, 996, 10.5588/ijtld.17.0174